Search
ACON · Company research

Aclarion, Inc. (ACON): Stock News & Events

Recent company-linked news records available in the database.

Main stock researchCompare stocks
RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

19records availableHealthcare

Stock News & Events data

Database-backed records only

19 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026Aclarion reported 85% year-over-year scan volume growth in Q3 2026 and 117% growth for the nine-month period. The company expanded its CLARITY clinical trial to eleven sites with updated enrollment criteria and published peer-reviewed data in the European Spine Journal supporting its Nociscan technology as an alternative to provocative discography. With $14.2 million in cash, Aclarion has runway into the second half of 2027 to fully fund the 300-patient trial.View source ↗GlobeNewswire Inc.Oct 20, 2026bullish11
Aclarion CEO is scheduled to speak in Los Angeles on Oct. 20 - Stock TitanAclarion CEO is scheduled to speak in Los Angeles on Oct. 20 Stock TitanView source ↗Stock TitanOct 13, 2026neutral00.6
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate EnrollmentAclarion announced revised inclusion/exclusion criteria for its CLARITY clinical trial to accelerate patient enrollment. The new criteria, approved at 9 of 11 active sites, better reflect real-world chronic low back pain patients while maintaining scientific rigor. The company expects meaningful enrollment acceleration and will provide an updated timeline for initial readout by year-end, though the overall trial duration remains on track.View source ↗GlobeNewswire Inc.Oct 8, 2026neutral01
A back-pain trial changed who can qualify at 9 of 11 sites. Aclarion expects faster enrollment. - Stock TitanA back-pain trial changed who can qualify at 9 of 11 sites. Aclarion expects faster enrollment. Stock TitanView source ↗Stock TitanOct 8, 2026neutral00.6
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate EnrollmentAclarion announced revised inclusion/exclusion criteria for its CLARITY clinical trial to accelerate patient enrollment. The new criteria, approved at 9 of 11 active sites, better reflect real-world chronic low back pain patients while maintaining scientific rigor. The company expects meaningful enrollment acceleration and will provide an updated timeline for initial readout by year-end, though the overall trial duration remains on track.View source ↗GlobeNewswire Inc.Oct 8, 2026neutral01
NYU Langone's spine center serves over 25,000 patients yearly. It joins a back-pain trial. - Stock TitanNYU Langone's spine center serves over 25,000 patients yearly. It joins a back-pain trial. Stock TitanView source ↗Stock TitanSep 29, 2026neutral00.6
ACON Q2 2026 Earnings: Wider -$1.12 Per-Share Loss Sends Shares Down 4.76% - Earnings Expansion Phase - dars.gov.etACON Q2 2026 Earnings: Wider -$1.12 Per-Share Loss Sends Shares Down 4.76% - Earnings Expansion Phase dars.gov.etView source ↗dars.gov.etAug 30, 2026neutral00.6
Insider Purchase: CFO of $ACON Buys 10,000 Shares - Quiver QuantitativeInsider Purchase: CFO of $ACON Buys 10,000 Shares Quiver QuantitativeView source ↗Quiver QuantitativeAug 18, 2026neutral00.6
Aclarion director Ryan Bond buys $50,059 in ACON shares - Investing.comAclarion director Ryan Bond buys $50,059 in ACON shares Investing.comView source ↗Investing.comAug 17, 2026neutral00.6
Aclarion Inc. (ACON) Slips 3.39% as Shares Approach Key $2.17 Support - Cash Secured Put - dars.gov.etAclarion Inc. (ACON) Slips 3.39% as Shares Approach Key $2.17 Support - Cash Secured Put dars.gov.etView source ↗dars.gov.etAug 11, 2026neutral00.6
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates - Yahoo FinanceAclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates Yahoo FinanceView source ↗Yahoo FinanceAug 6, 2026neutral00.6
Aclarion (ACON) Slips 1.69% to $2.32: Stock Presses Against Support at $2.20 - Virgin POC - dars.gov.etAclarion (ACON) Slips 1.69% to $2.32: Stock Presses Against Support at $2.20 - Virgin POC dars.gov.etView source ↗dars.gov.etAug 4, 2026neutral00.6
Aclarion (ACON) Slips 1.69% to $2.32: Stock Presses Against Support at $2.20 - Daily Profile - dars.gov.etAclarion (ACON) Slips 1.69% to $2.32: Stock Presses Against Support at $2.20 - Daily Profile dars.gov.etView source ↗dars.gov.etAug 4, 2026neutral00.6
Aclarion (ACON) Upgraded to Buy: Here's Why - Yahoo FinanceAclarion (ACON) Upgraded to Buy: Here's Why Yahoo FinanceView source ↗Yahoo FinanceMay 19, 2026neutral00.6
Aclarion CEO Bets On Bigger AI MedTech’s Playbook To Revive Sagging Stock - StocktwitsAclarion CEO Bets On Bigger AI MedTech’s Playbook To Revive Sagging Stock StocktwitsView source ↗StocktwitsMar 5, 2026neutral00.6
Ondas Stock Shot Up 11% Today – What’s Driving The Investor Optimism? - StocktwitsOndas Stock Shot Up 11% Today – What’s Driving The Investor Optimism? StocktwitsView source ↗StocktwitsMar 5, 2026neutral00.6
ACON Stock Pops 45% Pre-Market Today: What’s Driving The Move? - StocktwitsACON Stock Pops 45% Pre-Market Today: What’s Driving The Move? StocktwitsView source ↗StocktwitsJan 8, 2026neutral00.6
Aclarion, Inc. (ACON) Stock Price, News, Quote & History - Yahoo! Finance CanadaAclarion, Inc. (ACON) Stock Price, News, Quote & History Yahoo! Finance CanadaView source ↗Yahoo! Finance CanadaAug 14, 2025neutral00.6
Why Is Aclarion (ACON) Stock Up 109% Today? - InvestorPlaceWhy Is Aclarion (ACON) Stock Up 109% Today? InvestorPlaceView source ↗InvestorPlaceJan 26, 2024neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.